News | July 06, 2024
Dabur India updates on Q1 FY25
Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25
Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness
Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
States urged to maintain a state of constant vigil through screening of pregnant women for Zika virus infection and monitoring the growth of foetus of expecting mothers who tested positive for Zika
The initiative aims to empower individuals to take proactive steps towards monitoring their health
Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
Offering testing, treatment and support to help stop the spread of HIV and other infectious diseases
DKSH’s Business Unit Consumer Goods further capitalizes on its position to strengthen the consumer health, nutrition, and baby care categories
Subscribe To Our Newsletter & Stay Updated
